Commentary: Somatostatin analogs —How we choose, and why

Octreotide long-acting release (LAR) has been used since the early 1990s to slow tumor growth in well differentiated neuroendocrine tumors (NETs). The original registration for octreotide LAR was for control of hormone-related symptoms; however, prolonged progression-free survival (PFS) was shown in the PROMID study, a randomized, double-blind, placebo-controlled trial in midgut NETs [1]. That study was not powered to evaluate overall survival, and the data were never submitted to regulatory authorities to seek an indication for octreotide LAR as an antineoplastic agent.

Source: Seminars in Oncology - August 4, 2017 Category: Cancer & Oncology Authors: Diane Reidy-Lagunes, Nitya Raj, Leonard Saltz Source Type: research